Heron Therapeutics Company Profile (NASDAQ:HRTX)

About Heron Therapeutics (NASDAQ:HRTX)

Heron Therapeutics logoHeron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company's product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company's SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:HRTX
  • CUSIP: N/A
  • Web: www.herontx.com
Capitalization:
  • Market Cap: $822.9 million
  • Outstanding Shares: 54,138,000
Average Prices:
  • 50 Day Moving Avg: $15.81
  • 200 Day Moving Avg: $14.97
  • 52 Week Range: $12.21 - $20.85
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.52
  • P/E Growth: -0.17
Sales & Book Value:
  • Annual Revenue: $13.42 million
  • Price / Sales: 61.32
  • Book Value: $1.28 per share
  • Price / Book: 11.88
Profitability:
  • EBIDTA: ($174,140,000.00)
  • Return on Equity: -451.80%
  • Return on Assets: -152.23%
Debt:
  • Debt-to-Equity Ratio: 0.36%
  • Current Ratio: 2.82%
  • Quick Ratio: 2.72%
Misc:
  • Average Volume: 772,647 shs.
  • Beta: 2.07
  • Short Ratio: 11.55
 

Frequently Asked Questions for Heron Therapeutics (NASDAQ:HRTX)

What is Heron Therapeutics' stock symbol?

Heron Therapeutics trades on the NASDAQ under the ticker symbol "HRTX."

How were Heron Therapeutics' earnings last quarter?

Heron Therapeutics, Inc. (NASDAQ:HRTX) released its earnings results on Wednesday, August, 9th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.90) by $0.10. The firm had revenue of $8.51 million for the quarter, compared to the consensus estimate of $4.53 million. View Heron Therapeutics' Earnings History.

Where is Heron Therapeutics' stock going? Where will Heron Therapeutics' stock price be in 2017?

9 analysts have issued 1-year price targets for Heron Therapeutics' stock. Their predictions range from $21.00 to $41.00. On average, they expect Heron Therapeutics' stock price to reach $31.43 in the next year. View Analyst Ratings for Heron Therapeutics.

What are analysts saying about Heron Therapeutics stock?

Here are some recent quotes from research analysts about Heron Therapeutics stock:

  • 1. According to Zacks Investment Research, "Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA. " (7/12/2017)
  • 2. Cowen and Company analysts commented, "Earlier today Heron stock dropped as much as 8.5% on seemingly no news." (5/26/2017)
  • 3. Cantor Fitzgerald analysts commented, "Expensive 1Q: HRTX reported 1Q17 EPS of ($1.00), below our estimated ($0.83). The difference is mainly attributed to higher than expected R&D spend, though we believe that should taper off through the year, providing some flexibility in cash runway. HRTX finished the quarter with $165M in cash." (5/11/2017)
  • 4. Needham & Company LLC analysts commented, "We initiate coverage of Heron Therapeutics, a commercial-stage specialty biopharma focused on novel extended-release injectables, at Buy with a $28 PT. HRTX made the transition to a commercial co. in 4Q16 with the launch of Sustol for CINV. Cinvanti, on file with FDA (likely 4Q17 PDUFA), will round out the CINV franchise. The main value driver, HTX-011, is an extended-release combination of bupivacaine/meloxicam in development for post-op pain management. HTX-011 successfully completed a comprehensive ph 2 program in various surgical procedures demonstrating superior efficacy to placebo and bupivacaine. HTX-011 will begin ph 3 development in 2017. Our valuation looks at the differentiated CINV assets and cash balance (~$215MM) as a floor value for HRTX, while the potential of HTX-011 remains mostly undervalued." (2/27/2017)

Are investors shorting Heron Therapeutics?

Heron Therapeutics saw a drop in short interest during the month of August. As of August 15th, there was short interest totalling 12,723,565 shares, a drop of 8.6% from the July 31st total of 13,920,842 shares. Based on an average daily trading volume, of 505,331 shares, the short-interest ratio is currently 25.2 days. Currently, 23.9% of the company's shares are sold short.

Who are some of Heron Therapeutics' key competitors?

Who are Heron Therapeutics' key executives?

Heron Therapeutics' management team includes the folowing people:

  • Kevin C. Tang, Independent Chairman of the Board
  • Robert Harvey Rosen, President, Director
  • Barry D. Quart Pharm.D., Chief Executive Officer, Director
  • Robert E. Hoffman, Chief Financial Officer, Senior Vice President - Finance, Principal Accounting Officer
  • Kimberly J. Manhard, Executive Vice President - Drug Development
  • David L. Szekeres, Senior Vice President, General Counsel, Business Development, Corporate Secretary
  • Michael A. Adam Ph.D., Senior Vice President - Regulatory Affairs and Quality
  • Thomas B. Ottoboni Ph.D., Senior Vice President - Pharmaceutical and Preclinical Research and Development
  • Sean T. Ristine, Vice President - Human Resources
  • Christian Waage, Director

Who owns Heron Therapeutics stock?

Heron Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Tang Capital Management LLC (0.00%), Franklin Resources Inc. (0.00%), FMR LLC (0.00%), Janus Henderson Group PLC (0.00%), Vanguard Group Inc. (0.00%) and State Street Corp (0.00%). Company insiders that own Heron Therapeutics stock include Kevin C Tang, Kimberly Manhard and Robert Rosen. View Institutional Ownership Trends for Heron Therapeutics.

Who sold Heron Therapeutics stock? Who is selling Heron Therapeutics stock?

Heron Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., State Street Corp, Tang Capital Management LLC, Brandywine Global Investment Management LLC, California State Teachers Retirement System and Old West Investment Management LLC. View Insider Buying and Selling for Heron Therapeutics.

Who bought Heron Therapeutics stock? Who is buying Heron Therapeutics stock?

Heron Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Vanguard Group Inc., Rubric Capital Management LP, BlueCrest Capital Management Ltd, Royce & Associates LP, Northern Trust Corp, National Asset Management Inc. and Mesirow Financial Investment Management Inc.. View Insider Buying and Selling for Heron Therapeutics.

How do I buy Heron Therapeutics stock?

Shares of Heron Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Heron Therapeutics' stock price today?

One share of Heron Therapeutics stock can currently be purchased for approximately $15.20.


MarketBeat Community Rating for Heron Therapeutics (NASDAQ HRTX)
Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  312 (Vote Outperform)
Underperform Votes:  106 (Vote Underperform)
Total Votes:  418
MarketBeat's community ratings are surveys of what our community members think about Heron Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Heron Therapeutics (NASDAQ:HRTX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 9 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $31.43 (106.77% upside)

Analysts' Ratings History for Heron Therapeutics (NASDAQ:HRTX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/18/2017Cantor FitzgeraldSet Price TargetBuy$31.00LowView Rating Details
8/16/2017Jefferies Group LLCReiterated RatingBuyLowView Rating Details
8/10/2017Noble FinancialReiterated RatingBuyHighView Rating Details
8/3/2017Cowen and CompanySet Price TargetBuy$40.00LowView Rating Details
7/18/2017AegisReiterated RatingBuy$33.00LowView Rating Details
2/27/2017Needham & Company LLCInitiated CoverageBuy -> Buy$28.00N/AView Rating Details
1/5/2017Leerink SwannSet Price TargetBuy$21.00N/AView Rating Details
11/9/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$41.00N/AView Rating Details
9/6/2016Lake Street CapitalReiterated RatingBuy$45.00N/AView Rating Details
9/24/2015Bank of America CorporationBoost Price TargetBuy$54.00N/AView Rating Details
(Data available from 9/23/2015 forward)

Earnings

Earnings History for Heron Therapeutics (NASDAQ:HRTX)
Earnings by Quarter for Heron Therapeutics (NASDAQ:HRTX)
Earnings History by Quarter for Heron Therapeutics (NASDAQ HRTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2017Q2 2017($0.90)($0.80)$4.53 million$8.51 millionViewN/AView Earnings Details
5/10/2017Q1 2017($0.94)($1.00)$1.96 million$3.63 millionViewN/AView Earnings Details
2/23/2017Q4 2016($1.17)($1.22)$1.07 million$1.28 millionViewN/AView Earnings Details
11/8/2016Q3 2016($1.17)($1.24)ViewN/AView Earnings Details
8/8/2016Q2($0.96)($1.17)ViewN/AView Earnings Details
5/5/2016Q1($0.92)($0.92)ViewN/AView Earnings Details
2/19/2016Q4($0.64)($0.87)ViewN/AView Earnings Details
11/6/2015Q3($0.67)($0.63)ViewN/AView Earnings Details
8/7/2015Q2 2015($0.65)($0.74)ViewN/AView Earnings Details
5/8/2015Q115($0.64)($0.70)ViewN/AView Earnings Details
3/13/2015Q4 2014($0.69)($0.71)ViewN/AView Earnings Details
11/6/2014Q3 2014($0.69)($0.66)ViewN/AView Earnings Details
8/4/2014Q2 2014($0.62)($0.78)ViewN/AView Earnings Details
5/8/2014Q1 2014($0.58)($0.74)ViewN/AView Earnings Details
3/5/2014($0.53)($0.75)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Heron Therapeutics (NASDAQ:HRTX)
2017 EPS Consensus Estimate: ($3.56)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.86)($0.86)($0.86)
Q2 20172($1.04)($0.99)($1.02)
Q3 20172($0.89)($0.80)($0.85)
Q4 20172($0.96)($0.72)($0.84)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Heron Therapeutics (NASDAQ:HRTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Heron Therapeutics (NASDAQ:HRTX)
Insider Ownership Percentage: 20.31%
Insider Trades by Quarter for Heron Therapeutics (NASDAQ:HRTX)
Institutional Ownership by Quarter for Heron Therapeutics (NASDAQ:HRTX)
Insider Trades by Quarter for Heron Therapeutics (NASDAQ:HRTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/24/2017Kimberly ManhardVPSell21,542$15.33$330,238.86View SEC Filing  
1/19/2017Kevin C TangDirectorBuy2,459,016$12.20$29,999,995.20View SEC Filing  
8/10/2016Robert RosenInsiderSell100,000$23.30$2,330,000.00View SEC Filing  
4/21/2016Robert RosenPresidentSell200,000$23.23$4,646,000.00View SEC Filing  
6/10/2015Kevin C TangDirectorBuy121,212$24.75$2,999,997.00View SEC Filing  
6/2/2015Kevin C TangDirectorBuy150,000$20.62$3,093,000.00View SEC Filing  
6/1/2015Kimberly ManhardDirectorSell2,708$21.17$57,328.36View SEC Filing  
6/25/2014Barry D QuartCEOBuy10,000$11.75$117,500.00View SEC Filing  
6/25/2014Kevin C TangDirectorBuy510,638$11.75$5,999,996.50View SEC Filing  
11/20/2013Barry D QuartCEOBuy1,000,000$0.40$400,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Heron Therapeutics (NASDAQ:HRTX)
Latest Headlines for Heron Therapeutics (NASDAQ:HRTX)
Source:
DateHeadline
thestreet.com logoInteresting HRTX Put And Call Options For November 17th
www.thestreet.com - September 20 at 12:40 AM
businesswire.com logoHeron Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference - Business Wire (press release)
www.businesswire.com - September 19 at 7:37 PM
americanbankingnews.com logoHeron Therapeutics, Inc. (HRTX) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - September 16 at 6:46 PM
nasdaq.com logoNotable Friday Option Activity: LEA, SEAS, HRTX
www.nasdaq.com - September 16 at 1:07 AM
americanbankingnews.com logo Brokerages Anticipate Heron Therapeutics, Inc. (HRTX) Will Post Quarterly Sales of $8.25 Million
www.americanbankingnews.com - September 15 at 9:48 AM
finance.yahoo.com logoHeron Therapeutics, Inc. – Value Analysis (NASDAQ:HRTX) : September 14, 2017
finance.yahoo.com - September 14 at 6:11 AM
americanbankingnews.com logoHeron Therapeutics, Inc. (HRTX) Expected to Post Earnings of -$0.87 Per Share
www.americanbankingnews.com - September 13 at 6:20 AM
finance.yahoo.com logoHeron Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HRTX-US : September 12, 2017
finance.yahoo.com - September 12 at 11:47 PM
finance.yahoo.com logoWhat Does Heron Therapeutics Inc’s (HRTX) Share Price Indicate?
finance.yahoo.com - September 9 at 1:12 AM
finance.yahoo.com logoHeron Therapeutics Shows Rising Relative Strength; Still Shy Of Key Threshold
finance.yahoo.com - September 6 at 7:34 PM
finance.yahoo.com logoHeron Therapeutics Shows Rising Price Performance With Jump To 82 RS Rating
finance.yahoo.com - August 31 at 5:56 AM
finance.yahoo.com logoHeron Therapeutics Trying To Close In On Key Technical Benchmark
finance.yahoo.com - August 29 at 8:11 PM
americanbankingnews.com logoHeron Therapeutics, Inc. (HRTX) Sees Significant Decrease in Short Interest
www.americanbankingnews.com - August 27 at 3:12 AM
americanbankingnews.com logoHeron Therapeutics, Inc. (HRTX) Upgraded to Hold by BidaskClub
www.americanbankingnews.com - August 26 at 4:56 PM
americanbankingnews.com logo Analysts Anticipate Heron Therapeutics, Inc. (HRTX) Will Announce Earnings of -$0.87 Per Share
www.americanbankingnews.com - August 25 at 8:18 PM
americanbankingnews.com logoFY2017 EPS Estimates for Heron Therapeutics, Inc. (HRTX) Cut by Analyst
www.americanbankingnews.com - August 23 at 8:38 AM
americanbankingnews.com logoHeron Therapeutics, Inc. (HRTX) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - August 22 at 9:06 PM
americanbankingnews.com logoHeron Therapeutics' (HRTX) "Buy" Rating Reiterated at Jefferies Group LLC
www.americanbankingnews.com - August 20 at 10:46 PM
americanbankingnews.com logoHeron Therapeutics, Inc. (HRTX) PT Set at $31.00 by Cantor Fitzgerald
www.americanbankingnews.com - August 19 at 11:32 PM
americanbankingnews.com logoHeron Therapeutics, Inc. (HRTX) Cut to Sell at BidaskClub
www.americanbankingnews.com - August 19 at 12:38 AM
seekingalpha.com logoHeron Therapeutics: Our Next Pick - Seeking Alpha
seekingalpha.com - August 14 at 7:51 PM
americanbankingnews.com logoBrokers Issue Forecasts for Heron Therapeutics, Inc.'s Q3 2017 Earnings (HRTX)
www.americanbankingnews.com - August 14 at 2:50 AM
americanbankingnews.com logoFY2020 EPS Estimates for Heron Therapeutics, Inc. (HRTX) Decreased by Jefferies Group
www.americanbankingnews.com - August 11 at 4:50 PM
americanbankingnews.com logoHeron Therapeutics, Inc. (HRTX) Rating Reiterated by Noble Financial
www.americanbankingnews.com - August 11 at 10:14 AM
finance.yahoo.com logoShould You Buy Heron Therapeutics (HRTX) Ahead of Earnings
finance.yahoo.com - August 11 at 3:02 AM
americanbankingnews.com logoHeron Therapeutics, Inc. (HRTX) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPS
www.americanbankingnews.com - August 11 at 12:40 AM
streetinsider.com logoHeron Therapeutics (HRTX) Initiates Phase 3 Program for HTX-011 in Postoperative Pain Following Successful End-of-Phase 2 Meeting with FDA
www.streetinsider.com - August 10 at 12:53 AM
streetinsider.com logoHeron Therapeutics (HRTX) Initiates Phase 3 Program for HTX-011 in Postoperative Pain Following Successful End-of ... - StreetInsider.com
www.streetinsider.com - August 9 at 7:50 PM
finance.yahoo.com logoHeron Therapeutics Announces Initiation of Phase 3 Program for HTX-011 in Postoperative Pain Following Successful End-of-Phase 2 Meeting with FDA
finance.yahoo.com - August 9 at 7:50 PM
finance.yahoo.com logoHeron Therapeutics Reports Financial Results for the Three and Six Months Ended June 30, 2017 and Recent Corporate Progress
finance.yahoo.com - August 9 at 7:50 PM
finance.yahoo.com logoHeron Therapeutics reports 2Q loss
finance.yahoo.com - August 9 at 7:50 PM
americanbankingnews.com logo Brokerages Anticipate Heron Therapeutics, Inc. (NASDAQ:HRTX) Will Post Quarterly Sales of $4.53 Million
www.americanbankingnews.com - August 9 at 7:24 AM
americanbankingnews.com logo-$0.95 Earnings Per Share Expected for Heron Therapeutics Inc (NASDAQ:HRTX) This Quarter
www.americanbankingnews.com - August 7 at 10:34 AM
americanbankingnews.com logoHeron Therapeutics, Inc. (HRTX) PT Set at $40.00 by Cowen and Company
www.americanbankingnews.com - August 6 at 6:28 PM
americanbankingnews.com logoHeron Therapeutics, Inc. (HRTX) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - July 28 at 9:09 PM
americanbankingnews.com logoShort Interest in Heron Therapeutics, Inc. (NASDAQ:HRTX) Decreases By 9.8%
www.americanbankingnews.com - July 28 at 2:21 AM
finance.yahoo.com logoETFs with exposure to Heron Therapeutics, Inc. : July 24, 2017
finance.yahoo.com - July 24 at 11:08 PM
americanbankingnews.com logoZacks: Analysts Anticipate Heron Therapeutics, Inc. (HRTX) Will Post Quarterly Sales of $4.53 Million
www.americanbankingnews.com - July 20 at 3:48 PM
americanbankingnews.com logoZacks: Brokerages Anticipate Heron Therapeutics, Inc. (HRTX) Will Post Earnings of -$0.95 Per Share
www.americanbankingnews.com - July 18 at 9:55 AM
americanbankingnews.com logoHeron Therapeutics, Inc. (NASDAQ:HRTX) Stock Rating Reaffirmed by Jefferies Group LLC
www.americanbankingnews.com - July 15 at 3:35 PM
finance.yahoo.com logoETFs with exposure to Heron Therapeutics, Inc. : July 14, 2017
finance.yahoo.com - July 15 at 12:43 AM
nasdaq.com logoHRTX Crosses Above Key Moving Average Level
www.nasdaq.com - July 14 at 2:53 AM
seekingalpha.com logoHeron Therapeutics Shows Potential In The Chemotherapy-Induced-Nausea Market
seekingalpha.com - July 10 at 7:34 PM
finance.yahoo.com logoHeron Therapeutics, Inc. – Value Analysis (NASDAQ:HRTX) : July 7, 2017
finance.yahoo.com - July 8 at 11:30 AM
finance.yahoo.com logoHeron Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HRTX-US : July 6, 2017
finance.yahoo.com - July 7 at 6:14 AM
americanbankingnews.com logoHeron Therapeutics, Inc. (NASDAQ:HRTX) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - July 3 at 6:52 PM
americanbankingnews.com logoHeron Therapeutics, Inc. Expected to Post FY2017 Earnings of ($3.32) Per Share (HRTX)
www.americanbankingnews.com - June 28 at 8:02 AM
americanbankingnews.com logoHeron Therapeutics, Inc. Forecasted to Post FY2018 Earnings of ($2.23) Per Share (HRTX)
www.americanbankingnews.com - June 27 at 10:14 AM
americanbankingnews.com logoHeron Therapeutics, Inc. (HRTX) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - June 24 at 11:32 PM
americanbankingnews.com logo Brokerages Anticipate Heron Therapeutics, Inc. (HRTX) Will Post Quarterly Sales of $4.53 Million
www.americanbankingnews.com - June 24 at 11:02 AM

Social

Chart

Heron Therapeutics (HRTX) Chart for Saturday, September, 23, 2017

This page was last updated on 9/23/2017 by MarketBeat.com Staff